Included in the formulation
Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):VED
АТХ:B.02.B.D.05 Coagulation factor VII
Pharmacodynamics:It is a zymogen serine protease VIIa, which triggers an external way of blood clotting.
Pharmacokinetics:After intravenous administration, the concentration in the blood plasma is 60-100%.
Half-life is 3-5 hours.
Indications:It is used for the treatment and prevention of bleeding disorders caused by the acquired or hereditary deficiency of the blood coagulation factor VII. Used for acute bleeding associated with surgery, vitamin K deficiency, hepatic insufficiency due to hepatitis, cirrhosis, toxic liver damage.
III.D65-D69.D68.2 Hereditary deficiency of other coagulation factors
XI.K70-K77.K72 Hepatic failure, not elsewhere classified
Contraindications:The syndrome of disseminated intravascular coagulation, age up to 6 years, individual intolerance.
Carefully:Cardiac ischemia, myocardial infarction, pregnancy and lactation.
Pregnancy and lactation:Recommendations for FDA - Category C.It is used with caution in pregnancy and lactation in cases where the expected effect exceeds the risk to the fetus and newborn.
Dosing and Administration:Intravenously sprayed or drip. The dose is calculated individually.
Side effects:Local Reactions: burning sensation at the injection site.
General reactions: hyperthermia.
Allergic reactions.
Overdose:Myocardial infarction, vein thrombosis, pulmonary embolism.
Treatment is symptomatic.
Interaction:It is forbidden to mix the drug with other medicines in one solution, a syringe or infusion set.
Special instructions:When treating in outpatient settings, it is not recommended to drive vehicles and work with moving machinery.